Telomerase and DNA repair in glioma

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 4, 2009, Pages 275-279

  Patel, R ^a   Shervington, A ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Chemotherapy; Glioma; hTERT; MGMT

Indexed keywords

DOUBLE STRANDED DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TELOMERASE;

CELL IMMORTALIZATION; CRYSTAL STRUCTURE; DNA METHYLATION; DNA REPAIR; ENZYME ACTIVITY; EPIGENETICS; GLIOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ANIMALS; DNA METHYLATION; DNA REPAIR; GLIOMA; HUMANS; LIFE EXPECTANCY; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TELOMERASE;

EID: 64549114927     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.02.006     Document Type: Review

References (58)

1. Wang L., Wei Q., Wang L.E., Aldape K.D., Cao Y., Okcu M.F., Hess K.R., El-Zein R., Gilbert M.R., Woo S.Y., Prabhu S.S., Fuller G.N., and Bondy M.L. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J. Clin. Oncol. 24 (2006) 1627-1632
2. Yin L.T., Fu Y.J., Xu Q.L., Yang J., Liu Z.L., Liang A.H., Fan X.J., and Xu C.G. Potential biochemical therapy of glioma cancer. Biochem. Biophys. Res. Commun. 362 (2007) 225-229
3. Fadul C.E., Wen P.Y., Kim L., and Olson J.J. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J. Neurooncol. 89 (2008) 339-357
4. Graham C.A., and Cloughesy T.F. Brain tumor treatment: chemotherapy and other new developments. Semin. Oncol. Nurs. 20 (2004) 260-272
5. Ohgaki H., and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170 (2007) 1445-1453
6. Kleihues P., and Cavenee W.K. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System (2000), IARC Press, Lyon Washington USA
7. Hegi M.E., Murat A., Lambiv W.L., and Stupp R. Brain tumors: molecular biology and targeted therapies. Ann.Oncol. 17 (2006) 191-197
8. Kleihues P., and Ohgaki H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol. 7 (1997) 1131-1136
9. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schuler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lutolf U.M., and Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64 (2004) 6892-6899
10. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., and Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343 (2000) 1350-1354
11. Parkinson J.F., Wheeler H.R., Clarkson A., McKenzie C.A., Biggs M.T., Little N.S., Cook R.J., Messina M., Robinson B.G., and McDonald K.L. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J. Neurooncol. 87 (2008) 71-78
12. Johannessen T.C., Bjerkvig R., and Tysnes B.B. DNA repair and cancer stem-like cells-potential partners in glioma drug resistance?. Cancer Treat. Rev. 34 (2008) 558-567
13. Liu L., and Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res. 12 (2006) 328-331
14. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4 (2004) 296-307
15. Fang Q., Kanugula S., and Pegg A.E. Function of domains of human O6-alkylguanine-DNA alkyltransferase. Biochemistry 44 (2005) 15396-15405
16. Daniels D.S., and Tainer J.A. Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O(6)-alkylguanine-DNA alkyltransferase. Mutat. Res. 460 (2000) 151-163
17. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., Otten P., Van M.G., de T.N., and Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10 (2004) 1871-1874
18. Gerson S.L. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20 (2002) 2388-2399
19. Collins V.P., and James C.D. Gene and chromosomal alterations associated with the development of human gliomas. FASEB J. 7 (1993) 926-930
20. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., and Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59 (1999) 793-797
21. Wibley J.E., Pegg A.E., and Moody P.C. Crystal structure of the human O(6)-alkylguanine-DNA alkyltransferase. Nucleic Acids Res. 28 (2000) 393-401
22. Levin N., Lavon I., Zelikovitsh B., Fuchs D., Bokstein F., Fellig Y., and Siegal T. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106 (2006) 1759-1765
23. Sabharwal A., and Middleton M.R. Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr. Opin. Pharmacol. 6 (2006) 355-363
24. Madhusudan S., and Middleton M.R. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 31 (2005) 603-617
25. Quinn J.A., Pluda J., Dolan M.E., Delaney S., Kaplan R., Rich J.N., Friedman A.H., Reardon D.A., Sampson J.H., Colvin O.M., Haglund M.M., Pegg A.E., Moschel R.C., McLendon R.E., Provenzale J.M., Gururangan S., Tourt-Uhlig S., Herndon J.E., Bigner D.D., and Friedman H.S. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20 (2002) 2277-2283
26. McMurry T.B. MGMT inhibitors-The Trinity College-Paterson Institute experience, a chemist's perception DNA Repair. (Amst) 6 (2007) 1161-1169
27. Hegi M.E., Liu L., Herman J.G., Stupp R., Wick W., Weller M., Mehta M.P., and Gilbert M.R. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26 (2008) 4189-4199
28. Patel R., Shervington L., Lea R., and Shervington A. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. Brain Res. 1188 (2008) 173-181
29. Tanaka S., Akimoto J., Kobayashi I., Oka H., and Ujiie H. Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction. Oncol. Rep. 20 (2008) 165-171
30. Sasai K., Nodagashira M., Nishihara H., Aoyanagi E., Wang L., Katoh M., Murata J., Ozaki Y., Ito T., Fujimoto S., Kaneko S., Nagashima K., and Tanaka S. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am. J. Surg. Pathol. 32 (2008) 1220-1227
31. Harley C.B., and Sherwood S.W. Telomerase, checkpoints and cancer. Cancer Surv. 29 (1997) 263-284
32. Reddel R.R. The role of senescence and immortalization in carcinogenesis. Carcinogenesis 21 (2000) 477-484
33. Dessain S.K., Yu H., Reddel R.R., Beijersbergen R.L., and Weinberg R.A. Methylation of the human telomerase gene CpG island. Cancer Res. 60 (2000) 537-541
34. Guilleret I., and Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp. Cell Res. 289 (2003) 326-334
35. De C.A., Lacroix L., Douarre C., Temime-Smaali N., Trentesaux C., Riou J.F., and Mergny J.L. Targeting telomeres and telomerase. Biochimie 90 (2008) 131-155
36. Moorhouse A.D., Haider S., Gunaratnam M., Munnur D., Neidle S., and Moses J.E. Targeting telomerase and telomeres: a click chemistry approach towards highly selective G-quadruplex ligands. Mol. Biosyst. 4 (2008) 629-642
37. Langford L.A., Piatyszek M.A., Xu R., Schold S.C., Jr J., and Shay W. Telomerase activity in human brain tumours. Lancet 346 (1995) 1267-1268
38. Shervington A., Patel R., Lu C., Cruickshanks N., Lea R., Roberts G., Dawson T., and Shervington L. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 1134 (2007) 45-52
39. Shervington A., and Patel R. Differential hTERT mRNA processing between young and older glioma patients. FEBS Lett. 582 (2008) 1707-1710
40. Harada K., Kurisu K., Tahara H., Tahara E., Ide T., and Tahara E. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J. Neurosurg. 93 (2000) 618-625
41. Feldser D.M., and Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11 (2007) 461-469
42. Chen Y.J., Hakin-Smith V., Teo M., Xinarianos G.E., Jellinek D.A., Carroll T., McDowell D., MacFarlane M.R., Boet R., Baguley B.C., Braithwaite A.W., Reddel R.R., and Royds J.A. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res. 66 (2006) 6473-6476
43. Dome J.S., Bockhold C.A., Li S.M., Baker S.D., Green D.M., Perlman E.J., Hill D.A., and Breslow N.E. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J. Clin. Oncol. 23 (2005) 9138-9145
44. Gertler R., Rosenberg R., Stricker D., Friederichs J., Hoos A., Werner M., Ulm K., Holzmann B., Nekarda H., and Siewert J.R. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J. Clin. Oncol. 22 (2004) 1807-1814
45. Komata T., Kanzawa T., Kondo Y., and Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene 21 (2002) 656-663
46. Gellert G.C., Dikmen Z.G., Wright W.E., Gryaznov S., and Shay J.W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer, Res. Treat. 96 (2006) 73-81
47. Shay J.W., and Keith W.N. Targeting telomerase for cancer therapeutics. Br. J. Cancer 98 (2008) 677-683
48. Vietor M., Winter S., Groscurth P., Naumann U., and Weller M. On the significance of telomerase activity in human malignant glioma cells. Eur. J. Pharmacol. 407 (2000) 27-37
49. Kleinschmidt-DeMasters B.K., Evans L.C., Bobak J.B., Lopez-Uribe D., Hopper D., Shroyer A.L., and Shroyer K.R. Quantitative telomerase expression in glioblastomas shows regional variation and down-regulation with therapy but no correlation with patient outcome. Hum. Pathol. 31 (2000) 905-913
50. Kim C.H., Cheong J.H., Bak K.H., Kim J.M., and Oh S.J. Prognostic implication of telomerase activity in patients with brain tumors. J. Korean Med. Sci. 21 (2006) 126-130
51. Ishibashi T., and Lippard S.J. Telomere loss in cells treated with cisplatin. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4219-4223
52. Shervington A., Pawar V., Menon S., Thakkar D., and Patel R. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol. Biol. Rep. (2008) 10.1007/s11033-008-9295-3
53. Kim C.H., Yoon J.S., Sohn H.J., Kim C.K., Paik S.Y., Hong Y.K., and Kim T.G. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model. Cancer Lett. 250 (2007) 276-283
54. Tchirkov A., Rolhion C., Kemeny J.L., Irthum B., Puget S., Khalil T., Chinot O., Kwiatkowski F., Perissel B., Vago P., and Verrelle P. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br. J. Cancer 88 (2003) 516-520
55. Ito H., Aoki H., Kuhnel F., Kondo Y., Kubicka S., Wirth T., Iwado E., Iwamaru A., Fujiwara K., Hess K.R., Lang F.F., Sawaya R., and Kondo S. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J. Natl. Cancer Inst. 98 (2006) 625-636
56. Masutomi K., Possemato R., Wong J.M., Currier J.L., Tothova Z., Manola J.B., Ganesan S., Lansdorp P.M., Collins K., and Hahn W.C. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8222-8227
57. Shervington A., and Patel R. Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. Oligonucleotides 18 (2008) 365-374
58. Tabori U., Wong V., Ma J., Shago M., Alon N., Rutka J., Bouffet E., Bartels U., Malkin D., and Hawkins C. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br. J. Cancer 99 (2008) 1129-1135